Skip to contentSkip to filters

We use cookies for analytics.

Research grant, Call number RFA-RM-27-007

Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)

National Institutes of Health

  • United States
  • Institution applies
  • Cell Biology, Biotechnology and
Related content

About

NIH Common Fund support to develop new senescence technologies, or adapt existing ones, that identify and characterise the heterogeneity of senescent cells within their tissue environments and secretomes, enabling new strategies to modulate senescent cells in vivo and to predict the outcomes of targeting them in human aging and disease. Awards are five-year, milestone-driven phased cooperative agreements: a two-year UG3 phase for technology development and feasibility, then, after administrative review, a three-year UH3 phase of optimisation and validation ending with a collaborative demonstration project within SenNet.

Topics

Eligibility

Covers: Direct costs up to US$400,000 per year in the UG3 phase and US$550,000 per year in the UH3 phase, for up to five years. The Common Fund intends to commit US$5.4 million total costs in FY2027 for up to nine awards.

U.S. organisations only; non-U.S. components and foreign subawards are not allowed.

grants.govfiles.simpler.grants.gov

U.S. organisations, including higher-education institutions, non-profits, for-profit companies, small businesses and governments, apply on behalf of PD/PIs. Non-U.S. entities and non-U.S. components of U.S. organisations are not eligible, and foreign subawards are not allowed. Applications must propose both the UG3 and UH3 phases together and are due by 5:00 p.m. local time on 23 November 2026.

Source: grants.gov